Mehdi Gasmi, VP, Pharmaceutical Development at Avalanche Biotechnologies, Inc. (AAVL), sold 9,000 shares at $39.06 ($347K) on 2015-04-07, disclosed to the SEC on 2015-04-08.
Scheduled sale ($347k) by VP, Pharmaceutical Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.59 | 8,708 | $336K | 96.7% |
| 2 | $39.06 | 292 | $11K | 3.3% |
| Total | $38.61 avg | 9,000 | $347K | 100% |
| Filing → |
| ADVM | SELL | 2020-06-18 | $563K | — | Filing → |
| ADVM | SELL | 2020-06-17 | $324K | — | Filing → |
| ADVM | SELL | 2020-05-22 | $100K | — | Filing → |